Sugi Predict

Sugi Predict / Compounds / SCHEMBL2020494

SCHEMBL2020494

SCHEMBL2020494

COC(=O)CCCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.47
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CA14 Q9ULX7 3/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ CA1 P00915 1/20 0.39
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GBA1 P04062 1/20 0.36
▸ CTSK P43235 2/20 0.35
▸ RECQL P46063 1/20 0.35
▸ KDM5A P29375 2/20 0.35
▸ LTA4H P09960 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9354449 0.95 TSHR (0.45) TSHRMEN1KMT2ACA14CA12
SCHEMBL903563 0.93 TSHR (0.44) TSHRMEN1KMT2ACA14CA12
SCHEMBL5884651 0.89 MEN1 (0.52) TSHRMEN1KMT2ACA14CA12
SCHEMBL23477345 0.88 HDAC6 (0.39) TSHRCA14HDAC1HDAC2HDAC6
SCHEMBL25473057 0.84 CA14 (0.53) TSHRMEN1KMT2ACA14CA12
SCHEMBL22113731 0.84 HDAC1 (0.41) TSHRMEN1KMT2ACA14CA12
SCHEMBL14822004 0.83 CYP1A2 (0.44) TSHRCA12CA2CA1HDAC1
SCHEMBL6256081 0.82 HDAC6 (0.40) CA14HDAC1HDAC2HDAC6ALDH1A1
SCHEMBL9219474 0.82 HDAC6 (0.40) CA14CA12CA1HDAC1HDAC2
SCHEMBL693386 0.82 HDAC6 (0.40) TSHRCA14HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 — — US disclosed
EP-4712961-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
EP-4688776-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN Acerta Pharma B.V. (NL) 2026-02-11 — — EP disclosed
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA BV (NL) 2025-11-27 — — US disclosed
WO-2024238633-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2024-11-21 — — WO disclosed
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA B.V. (NL) 2024-10-10 — — US disclosed
WO-2024201240-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN ACERTA PHARMA B.V. (NL) 2024-10-03 — — WO disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
CN-114405547-A Metal complexes 利兹大学 2022-04-29 — — CN disclosed
WO-1997040011-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R. J. REYNOLDS TOBACCO COMPANY (US) 1997-10-30 — — WO disclosed
EP-0801646-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R.J. REYNOLDS TOBACCO COMPANY (US) 1997-10-22 — — EP disclosed
EP-0801527-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R.J. REYNOLDS TOBACCO COMPANY (US) 1997-10-22 — — EP disclosed
US-5616707-A N-METHYL-4-PYRIDYL-3-BUT(ENE OR YNE)-1-AMINE TARGACEPT, INC. 1997-04-01 — — US disclosed
US-5616716-A (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds TARGACEPT, INC. 1997-04-01 — — US disclosed
US-5604231-A NON-STEROIDAL ANTIINFLAMMATORY AGENTS, DOPAMINERGIC AGENTS; SIDE EFFECT REDUCTION TARGACEPT, INC. 1997-02-18 — — US disclosed
US-5597919-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS RESULTING FROM NEUROTRANSMITTER DYSFUNCTION TARGACEPT, INC., A CORPORATION OF DELAWARE 1997-01-28 — — US disclosed
WO-1996020929-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R.J. REYNOLDS TOBACCO COMPANY (US) 1996-07-11 — — WO disclosed
WO-1996020599-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF ULCERATIVE COLITIS R.J. REYNOLDS TOBACCO COMPANY (US) 1996-07-11 — — WO disclosed
WO-1996020600-A1 PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS R.J. REYNOLDS TOBACCO COMPANY (US) 1996-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC TSHR 4174/4885MEN1 2531/4885KMT2A 3283/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 TSHR 1591/4885MEN1 1/4885KMT2A 1016/4885
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 TSHR 1223/4885MEN1 1/4885KMT2A 3738/4885
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 TSHR 1223/4885MEN1 1/4885KMT2A 3738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.